Skip to main content
. 2019 Nov 29;10(1):23–34. doi: 10.1016/j.jpha.2019.11.008

Fig. 1.

Fig. 1

(A) N-glycan profiles of bevacizumab (blue), trastuzumab (green), infliximab (orange) and rituximab (pink) drug products analysed via intact mass analysis in denaturing (dark colour shade) and native (light colour shade) conditions. Relative abundancies were calculated on the basis of MS signal intensities obtained after raw data deconvolution and averaged on triplicate analysis. Comparison of intact protein mass spectrometry in denaturing (B) and native (C) conditions.